Close Menu

Myriad

Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.

Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.

The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.

The firm reported total revenu 16.8 million, up from $187.9 million in Q2 2018 and just above analysts' average estimate.  

The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

Among the firms presenting, 10x noted that it doubled its revenue growth in 2018, and Myriad discussed the impact that new tests are having on its growth.

Data from the GUIDED study will be central to commercial payor discussions, a Medicare LCD reconsideration request, and eventually expansion into the primary care market.

The investment bank upgraded the company's stock to an Outperform rating from Market Perform but lowered its price target to $37 per share.

Pages

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.